Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 82

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 82
---
 This dissolution analysis has been prepared by, and is the responsibility of, the Company’s management. Ernst & Young LLP has not audited, reviewed, examined, compiled nor applied agreed upon procedures with respect to the accompanying dissolution analysis prospective financial information and, accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. The Ernst & Young LLP report incorporated by reference in this document relates to the Company’s previously issued financial statements. It does not extend to the dissolution analysis and should not be read to do so. Financing The Purchaser’s obligations under the Agreement are not subject to any conditions regarding the Purchaser’s ability to obtain financing for the Consideration to be paid pursuant to the Arrangement. Transaction Expenses We expect that the professional fees and other expenses required to complete the Arrangement and related transactions will be approximately US$9.6 million. See “ Fees and Expenses” for a description of the fees and expenses expected to incur in connection with the transaction. Interests of the Company’s Directors and Executive Officers in the Arrangement In considering the recommendation of the Board that you vote in favor of the Arrangement Resolution, you should be aware that aside from their interests as Shareholders of the Company, the Company’s directors and executive officers have interests in the Arrangement that are different from, or in addition to, those of other Shareholders of the Company generally. In particular, certain directors and executive officers are entitled to 47

“collateral benefit” (as defined in MI 61-101)in connection with the transaction (see “ Interests of the Company’s Directors and Executive Officers in the Arrangement — Canadian Securities Law Matters”). Additionally, these interests include indemnification of our directors and executive officers following the completion of the Arrangement. The members of the Transaction Committee were aware of and considered these interests, among other matters, in evaluating and negotiating the Agreement and the Arrangement and in making its recommendations to the Board, which was also aware of and took into account these interests, among other matters, when making its recommendation to the Shareholders to vote for the Arrangement Resolution and the Compensation Resolution.See “ The Arrangement — Background of the Arrangement,” “ The Arrangement —; Recommendation of the Transaction Committee; Reasons for the Arrangement; Recommendation of the Board; and Opinion of Leerink Partners” and “ Interests of the Company’s Directors and Executive Officers in the Arrangement.” The Shareholders should take these interests into account in deciding whether to vote “FOR” the Arrangement